Beacon Biosignals is a neurotechnology company focused on bringing precision neuroscience into clinical trials and treatments for brain- and sleep-related disorders. The company’s core offering includes an FDA-cleared wearable device (the Waveband headband) that captures high-fidelity EEG during sleep and wake states, combined with an AI-driven analytics platform that processes millions of hours of neural data to extract biomarkers of brain function. Its end-to-end solution supports pharmaceutical and biotech clients by providing tools for patient stratification, dose-response monitoring, and early-stage disease progression, enabling trials to be more precise and efficient.
Total raised
$132M
Last stage
Series B
Investors
M. Brandon Westover
MD/PhD in Physics; board-certified neurologist and clinical neurophysiologist/epileptologist at Massachusetts General Hospital; directs the MGH Critical Care EEG Monitoring Service and Clinical Data Animation Center.
LinkedInJarrett Revels
Co-founded Beacon Biosignals in 2019. Serves on the board of 1 company.
Sydney Cash
Co-founded Beacon Biosignals in 2019.
Jacob Donoghue
MD from Harvard Medical School and PhD in Neuroscience from MIT. Previously a researcher at Massachusetts General Hospital. Leads Beacon's efforts in AI-powered EEG analytics for brain health.
LinkedInNo applications, no recruiter spam. Just the intro.
A few questions to make sure this role is the right shape for you. Two minutes.
I write the intro, send it to the founder, and handle the back-and-forth.
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.